Chargement en cours...
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
BACKGROUND: Activated drotrecogin alfa (human activated protein C, rhAPC), is produced by recombinant DNA technology, and purports to improve clinical outcomes by counteracting the inflammatory and thrombotic consequences of severe sepsis. Controversy exists around the clinical benefits of this drug...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2007
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1929064/ https://ncbi.nlm.nih.gov/pubmed/17592639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2253-7-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|